UF among nation’s leaders in startups, licensing and life-sciences tech transfer


aundice, chronic bronchitis, and other lung and liver problems are a daily struggle for the 1 in 2,500 Americans with alpha-1 antitrypsin deficiency, a genetic condition that can cause serious lung disease in adults or liver disease at any age.

About 19 million people in the U.S. who do not have these symptoms carry the defective gene that causes this disorder and could pass the gene on to their children.

A University of Florida startup, Geneaidyx hopes to improve the lives of individuals with alpha-1 antitrypsin deficiency and their families by developing cutting-edge technologies to improve early detection. It’s one of 16 startups based on UF research discoveries launched by the UF Office of Technology Licensing in fiscal year 2014.